Financial Results for the Fourth quarter and year ended 31st March, 2026
ALBERTDAVD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.1 pts less than Nifty Microcap 250 and 9.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Albert David Limited reported audited FY2026 results with revenue from operations at Rs 33,359.81 Lacs (vs Rs 34,576.80 Lacs prior year), a marginal decline. The company swung to a net loss of Rs 149.47 Lacs for the year compared to a net profit of Rs 1,720.08 Lacs in FY2025, largely due to lower other income (Rs 745.33 Lacs vs Rs 2,958.07 Lacs). Profit before tax dropped sharply to Rs 52.49 Lacs from Rs 2,522.77 Lacs. The Board appointed Mr. Amit Mahla as CEO effective May 12, 2026, filling a vacancy since Mr. Umesh Manohar Kunte resigned as Managing Director & CEO on December 18, 2025. Mr. Mahla brings 28+ years of pharma experience from companies including Cipla, Sun Pharma, and JB Pharma. A final dividend of Rs 5 per share (50% on Rs 10 face value) has been recommended, subject to shareholder approval at the August 6, 2026 AGM. Statutory auditors L.B. Jha & Co. issued an unmodified opinion.
The significant profit decline and net loss for FY2026 may weigh on investor sentiment. The appointment of an experienced external CEO may provide stability going forward. The 50% dividend payout signals confidence despite weak profitability.